Syngene International Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/138ch92v31aqsuk5x5i0rtt4.pdf

Key Takeaways


Zoetis Partnership & Manufacturing Milestone

Hunt: "We are on track for the next important regulatory audits which will pave the way for the commercial manufacturing of the drug substance for Librela®, a Zoetis product, from the fourth quarter of FY23. With a strong first half of the year behind us we are on track to achieve our guidance, including the upgraded revenue growth target announced in July."*

Divisional Performance


Margins & Cost Structure

Biswas: "Forward planning with suppliers prevented supply chain disruption and, despite the rising global inflation, cost discipline helped us maintain EBITDA margins at similar levels as last year."

Market Environment & Investment

Biswas: "Overall, we are seeing healthy signs of growth in the market for contract research, development and manufacturing services and we continue to invest in infrastructure and capability development to meet these opportunities."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growthOn track to achieve upgraded revenue growth target announced in JulyFY23
Zoetis commercial manufacturingBegin commercial manufacturing of drug substance for Librela®Q4 FY23, subject to successful regulatory audits
Zoetis agreement valuePotential to be worth up to $500 millionOver the next 10 years

Key Metrics

MetricQ2 FY23
Revenue from operations₹768 crores, up 26% YoY
Reported EBITDA₹232 crores, up 22% YoY
EBITDA margin29.6%, vs 30.5% YoY (28.2% from operations margin vs 29.1% YoY)
PAT before exceptional item₹102 crores, up 11% YoY
PAT margin13.0%, vs 14.8% YoY
PAT after exceptional item₹102 crores, up 53% YoY (Q2 FY22: ₹67 crores after SEIS adjustment)
H1 FY23 revenue from operations₹1,413 crores, up 17% YoY
H1 FY23 PAT before exceptional item₹176 crores, up 4% YoY
Staff costs218.5 crore (28.4% of revenue), vs 189.2 crore (31.0%) YoY
Finance costs11.7 crore, vs 1.2 crore YoY
Forex gain18.6 crore, vs loss of 10.4 crore YoY
Depreciation and amortisation90.2 crore, vs 76.2 crore YoY
Zoetis agreement potentialUp to $500 million over 10 years
ScientistsMore than 5,200